Medicus Pharma Ltd (TSE:MDCX) has released an update.
Medicus Pharma Ltd has announced the pricing of its $4 million initial public offering in the U.S., with shares and warrants set to begin trading on Nasdaq. The company plans to use the funds to advance clinical trials for its innovative skinpatch treatment for basal cell carcinoma. The IPO is expected to close on November 15, 2024, under customary conditions, with Maxim Group LLC managing the offering.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
